TN2016000064A1 - Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes - Google Patents
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetesInfo
- Publication number
- TN2016000064A1 TN2016000064A1 TN2016000064A TN2016000064A TN2016000064A1 TN 2016000064 A1 TN2016000064 A1 TN 2016000064A1 TN 2016000064 A TN2016000064 A TN 2016000064A TN 2016000064 A TN2016000064 A TN 2016000064A TN 2016000064 A1 TN2016000064 A1 TN 2016000064A1
- Authority
- TN
- Tunisia
- Prior art keywords
- dimethylpropan
- aminium
- carboxy
- ethyl
- pharmaceutically acceptable
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 230000037058 blood plasma level Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts to decrease blood plasma levels of insulin and glucose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13186201 | 2013-09-26 | ||
| PCT/IB2014/064514 WO2015044828A1 (en) | 2013-09-26 | 2014-09-15 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2016000064A1 true TN2016000064A1 (en) | 2017-07-05 |
Family
ID=49231372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2016000064A TN2016000064A1 (en) | 2013-09-26 | 2014-09-15 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN105530929B (en) |
| AR (1) | AR099638A1 (en) |
| BR (1) | BR112016004211B1 (en) |
| CA (1) | CA2924682C (en) |
| JO (1) | JO3333B1 (en) |
| MX (1) | MX368505B (en) |
| TN (1) | TN2016000064A1 (en) |
| WO (1) | WO2015044828A1 (en) |
| ZA (1) | ZA201600894B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2067474A1 (en) * | 2007-12-05 | 2009-06-10 | Grindeks, a joint stock company | Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate |
| LV14345B (en) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4- [Ethyl (dimethyl) ammonium] butano ā and t ā uses š an cardiovascular ā ro slim ī bu ā rst ē š |
| GEP20156373B (en) | 2011-04-27 | 2015-09-25 | Grindeks Jsc | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2014
- 2014-08-05 JO JOP/2014/0244A patent/JO3333B1/en active
- 2014-08-13 AR ARP140103039A patent/AR099638A1/en unknown
- 2014-09-15 CN CN201480050485.3A patent/CN105530929B/en active Active
- 2014-09-15 MX MX2016003347A patent/MX368505B/en active IP Right Grant
- 2014-09-15 WO PCT/IB2014/064514 patent/WO2015044828A1/en not_active Ceased
- 2014-09-15 TN TN2016000064A patent/TN2016000064A1/en unknown
- 2014-09-15 CA CA2924682A patent/CA2924682C/en active Active
- 2014-09-15 BR BR112016004211-5A patent/BR112016004211B1/en active IP Right Grant
-
2016
- 2016-02-09 ZA ZA2016/00894A patent/ZA201600894B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201600894B (en) | 2017-05-31 |
| CA2924682C (en) | 2018-02-27 |
| MX2016003347A (en) | 2016-06-24 |
| MX368505B (en) | 2019-10-04 |
| WO2015044828A1 (en) | 2015-04-02 |
| BR112016004211B1 (en) | 2022-09-06 |
| CA2924682A1 (en) | 2015-04-02 |
| CN105530929B (en) | 2018-03-02 |
| AR099638A1 (en) | 2016-08-10 |
| JO3333B1 (en) | 2019-03-13 |
| CN105530929A (en) | 2016-04-27 |
| BR112016004211A2 (en) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500115B1 (en) | Glucagon analogues | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
| GB201314512D0 (en) | Dual Haemodialysis and Haemodiafiltration blood treatment device | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| EP3013219A4 (en) | Low glucose treatment for people with diabetes | |
| SA517381678B1 (en) | Dihydropyrimidin-2-One Compounds and Medical Use Thereof | |
| MX2016011881A (en) | Dry-powder peptide medicament. | |
| MX368734B (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine. | |
| MX2017001737A (en) | Vitamin b2 and its use. | |
| MX2013009456A (en) | Vinyl -aryl - sulfones for use in peritoneal carcinomatosis. | |
| JO3333B1 (en) | Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes | |
| PT2699545T (en) | Novel amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome | |
| PH12015500306A1 (en) | Arry-520 for use in treating cancer in a patient with low aag | |
| SG10201809418VA (en) | New administration routes of insulin, insulin analogs or derivatives of insulin | |
| PL2852400T3 (en) | An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes | |
| HK1220133A1 (en) | Methods of improving microvascular integrity | |
| AU2014903587A0 (en) | Regulation of a blood glucose level in a patient with diabetes | |
| PH12015500178B1 (en) | Injectable supersaturated acetaminophen solution for spinal administration | |
| IN2014DE00818A (en) | ||
| UA74052U (en) | Method for preventing lateral abdominal wall hernia in patients with functioning colostoma and ventral hernia | |
| UA97741C2 (en) | Method for regeneration of skin integuments in patients with deep burns by microautodermotransplants | |
| GB201304462D0 (en) | Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance | |
| UA86338U (en) | Method for treating gestational diabetes | |
| UA74770U (en) | method for treating patients with chronic hepatobiliary pathology on the background of enhanced fatigue syndrome |